Drug Trial Radar · NCT06008925
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
43
Planned (sponsor's estimate)
Start
Nov 17, 2022
Primary completion
Dec 2025
Study completion Jun 2026
Sponsor
- Lead sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection. This study will be conducted in combination with nivolumab injection in HSV seropositive subjects with advanced metastatic gastric or gastroesophageal junction adenocarcinoma who have previously received two or more systemic treatment regimens (which must include anti-PD-1 monoclonal antibodies). This is an open-label study divided into two parts. Part 1: This part is an escalating dose trial to explore the safety of the combination and determine the recommended safe dose of the combination. Part 2: This part is an extension trial to investigate the preliminary efficacy of the combination at a safe dose.
Conditions
- Metastatic Gastric Cancer
Interventions
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))Drug
Intratumoral injection only. Dosing days may be Day 1 or Days 1-3 only.
Nivolumab InjectionDrug
Administered once at 3 mg/kg intravenously on Days 8 and 22 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib:RP2D/MTDTime frame: through Phase Ib study completion, an average of 1 year
- Phase Ib:Incidence and number of DLTTime frame: through Phase Ib study completion, an average of 1 year
- Phase Ib and Phase IIa:AE, SAE occurrence and frequencyTime frame: through Phase Ib and Phase IIa study completion, an average of 2 year
- Phase IIa:ORRTime frame: through Phase IIa study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.